Table 2.

Mortality for HCV+ versus HCV− patients (DOPPS phases 1–5, 1996–2015)

EventNo. of EventsCrude RateaUnadjusted HRb (95% CI)Adjusted HRc (95% CI)
All-cause mortality15,807139.51.02 (0.95 to 1.09)1.12 (1.05 to 1.20)d
Cardiovascular679065.80.97 (0.87 to 1.07)1.10 (0.98 to 1.22)
Infection218721.21.05 (0.88 to 1.27)1.11 (0.91 to 1.34)
Hepatic-relatede1131.15.88 (3.84 to 8.99)d5.90 (3.67 to 9.50)d
  • n=73,577 patients included in all-cause models. n=65,015 patients included in cause-specific models as large United States dialysis organizations in DOPPS phases 4 and 5 were excluded because of differential reporting of cause of mortality. Facilities reporting zero deaths during DOPPS follow-up or having <5 cumulative patient-years of mortality follow-up were excluded. HCV+, hepatitis C virus-positive; HCV−, hepatitis C virus-negative; DOPPS, Dialysis Outcomes and Practice Patterns Study; HR, hazard ratio; 95% CI, 95% confidence interval.

  • a Events per 1000 patient years.

  • b Stratified by DOPPS country (United States black and nonblack patients considered as separate strata) and phase and accounting for facility clustering.

  • c Stratified by DOPPS country (United States black and nonblack patients considered as separate strata) and phase and accounting for facility clustering; adjusted for age, sex, time on dialysis, 13 summary comorbidities and hepatitis B infection, and albumin, phosphorus, and creatinine levels.

  • d P<0.05.

  • e Includes hepatitis, cirrhosis, or liver failure as primary or secondary cause of death.